Lenvatinib can be efficacious and safe for treating advanced HCC patients previously treated with Atz/Bev, and AEs such as anorexia and general fatigue can be effectively managed without losing lenvatinib's therapeutic benefits.
No takes yet. Share an insight, caveat, or question.
Muto et al. (2023) studied this question.